Clincosm LogoSign in Get a demo

Efficacy of Acapella on Spirometry Measures in Patients With Bronchiectasis

Sponsor
South Valley University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05838144
Collaborator
(none)
20
Enrollment
1
Location
2
Arms
1.6
Anticipated Duration (Months)
12.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

  1. Acapella group. Will use Acapella device for 3 times per day for 15 minutes for 7 days beside medications and routine chest physical therapy program .

  2. Only routine physical therapy program group ( control group). Will only take medications and routine chest physical therapy program.

Condition or Disease Intervention/Treatment Phase
  • Device: Acapella device
  • Other: Only routine chest physical therapy program
 N/A

Detailed Description

  1. Acapella group.Will use Acapella device for 3 times per day for 15 minutes for 7 days beside medications and routine chest physical therapy program.

  2. Only routine physical therapy program group( control group). Will only take medications and routine chest physical therapy program Spirometer measures such as forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) will be measured for every patient before and after the end of 7 days.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Efficacy of Acapella on Spirometry Measures in Patients With Bronchiectasis.
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
May 30, 2023
Anticipated Study Completion Date :
Jun 20, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Acapella

Will use Acapella device 3 times per day for 15 minutes for 7 days beside medications and routine physical therapy program.

Device: Acapella device
Group A. Will use Acapella device.

Other: Only routine chest physical therapy program
Group B. Will take medications and perform routine chest physical therapy program.
Placebo Comparator: Only routine physical therapy program

Only they will receive medications and routine physical therapy program.

Other: Only routine chest physical therapy program
Group B. Will take medications and perform routine chest physical therapy program.

Outcome Measures

Primary Outcome Measures

  1. Spirometry measures [7 days]

    FVC, FEV1

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  1. bronchiectasis patients.

  2. Age range between 40 to 55 years old of both gender.

  3. Cooperative patients.

Exclusion Criteria:

  1. Patients with severe cardiac disorders.

  2. Un controlled hypertensive patients.

  3. Un controlled diabetic patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shymaa yussuf abo zaid Cairo Egypt

Sponsors and Collaborators

  • South Valley University

Investigators

  • Principal Investigator: Shymaa Y Abo zaid, Lecturer

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shymaa yussuf abo zaid, Lecturer, South Valley University
ClinicalTrials.gov Identifier:
NCT05838144
Other Study ID Numbers:
  • PT-IMG-02/2023-505
First Posted:
May 1, 2023
Last Update Posted:
May 1, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Bronchiectasis

Study Results

No Results Posted as of May 1, 2023